DEFA14A: STAAR Surgical Merger with Alcon: Analysts Endorse Revised Deal

STAAR Surgical Company reports independent industry analysts and ISS recommend stockholders vote FOR the amended Alcon merger agreement at an increased price of $30.75 per share.

Summary

• An amended merger agreement with Alcon provides STAAR stockholders with $30.75 per share in cash upon consummation of the transaction.
• This price represents a 74% premium to STAAR's 90-day Volume Weighted Average Price as of August 4, 2025, and a 66% premium to the closing price of STAAR common stock on the same date.
• Independent industry analysts from BTIG, Canaccord Genuity, Mizuho, and Needham have recognized the value and merits of the Alcon transaction.
• Institutional Shareholder Services (ISS) has issued an updated report recommending that STAAR stockholders vote FOR the Alcon transaction, citing that valuation uncertainties are outweighed by acute downside risks and improved terms.
• The STAAR Board of Directors recommends stockholders vote FOR the Alcon merger on the WHITE proxy card.
• A virtual Special Meeting of Stockholders is scheduled for December 19, 2025, at 8:30 a.m. (Pacific Time).
• Stockholders of record as of October 24, 2025, are entitled to vote at the meeting.

Sentiment

Score: 9

Explanation: The filing conveys a highly positive sentiment regarding the Alcon merger, emphasizing the significant premium offered to stockholders and the strong endorsement from independent analysts and a key proxy advisory firm. It strongly advocates for the transaction as the best path forward for shareholder value.

Positives

• The Alcon merger price increased to $30.75 per share in cash.
• The offer represents a 74% premium to STAAR's 90-day Volume Weighted Average Price as of August 4, 2025.
• The offer represents a 66% premium to STAAR's closing price on August 4, 2025.
• Independent industry analysts and Institutional Shareholder Services (ISS) recommend the transaction.
• The go-shop period expired without any other proposals, indicating limited interest from other potential acquirers.
• The $1.6 billion all-in takeout valuation prices the transaction at approximately ~4.5x on a forward EV/Sales basis (using blended 2026-2027 estimates), which is comparable to smid-cap growth peers (4x to 6x range).
• The proposed offer is in-line with recent deals across the US Medtech space, suggesting a fair exit multiple.

Negatives

• BTIG analysts suggest STAAR shares are likely to meaningfully suffer if the deal is not consummated.
• ISS states that uncertainties about valuation are now outweighed by more acute downside risks if the Alcon agreement is not approved.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Alcon merger agreement or cause the consummation of the proposed transaction to be delayed or to fail to occur.
• The failure to obtain approval of the proposed transaction from STAAR's stockholders.
• The failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers, and others with whom it does business, or on its operating results and business generally.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The primary future outlook centers on the successful consummation of the Alcon merger. The company and analysts anticipate a positive outcome for stockholders if the transaction closes, with a significant cash premium. Conversely, there are explicit warnings of potential stock price decline and acute downside risks if the merger fails to occur.

Management Comments

• The STAAR Board of Directors recommends that stockholders vote FOR the Alcon merger on the WHITE proxy card TODAY to protect the value of their investment.

Industry Context

The proposed acquisition of STAAR Surgical by Alcon, a global leader in eye care, signifies a consolidation within the ophthalmic medical technology sector. STAAR's specialization in phakic IOLs, particularly the EVO ICL, complements Alcon's broader portfolio. The valuation metrics, such as the ~4.5x forward EV/Sales multiple, are benchmarked against smid-cap growth peers in the Medtech space, suggesting the deal aligns with prevailing industry valuation standards for companies with similar growth profiles. The absence of competing bids after the go-shop period indicates that the current offer is likely the most attractive available in the market for STAAR's specific niche.

Comparison to Industry Standards

• The ~4.5x proposed exit multiple on a forward EV/Sales basis (using blended 2026-2027 estimates) is comparable to smid-cap growth peers with a topline growth profile of 10%+ which trade in the 4x to 6x range on 2026/2027 estimates.
• The proposed offer is in-line with recent deals across the US Medtech space.

Stakeholder Impact

• Shareholders are expected to receive a significant cash premium of $30.75 per share, representing a 74% premium to the 90-day VWAP and a 66% premium to the closing price as of August 4, 2025. However, there is a risk of significant stock price decline if the merger is not consummated.
• Employees may experience disruption to management's attention from ongoing business operations, and there are risks related to the ability to retain and hire key personnel.
• Customers and suppliers may see impacts on their relationships with STAAR due to the proposed transaction.

Next Steps

• Stockholders are urged to vote FOR the Alcon merger on the WHITE proxy card.
• Attend the virtual Special Meeting of Stockholders on December 19, 2025, at 8:30 a.m. (Pacific Time).

Key Dates

Recommendation

The filing strongly advocates for the approval of the Alcon merger, which offers a significant cash premium of $30.75 per share. This represents a substantial premium over recent trading prices and is endorsed by independent analysts and ISS, suggesting a favorable exit for current shareholders. Holding shares until the merger closes allows shareholders to realize this premium. The primary risk is the deal not closing, which could lead to a significant stock price decline.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Proxy Statement, EVO ICL, Phakic IOLs, Vision Correction, Medtech, Shareholder Vote